Navigation Links
BIDMC scientists awarded grants from Michael J. Fox Foundation for Parkinson's research

BOSTON -- Beth Israel Deaconess Medical Center (BIDMC) neurologists Alvaro Pascual-Leone, MD, PhD, and Daniel Tarsy, MD, have been awarded grants totaling more than $1.5 million from the Michael J. Fox Foundation for Parkinson's Research (MJFF) to conduct investigations aimed at improving the quality of life for patients with Parkinson's disease.

A chronic, degenerative disorder of the nervous system that affects one in 100 individuals over age 60, Parkinson's disease results from diminished levels of dopamine, the brain's chemical messenger responsible for transmitting the signals that enable us to coordinate movements. Although Parkinson's disease typically results in tremor, rigidity and other motor symptoms, a number of non-motor symptoms, including depression, cognitive impairment, and sleep problems can also affect patients with Parkinson's disease and, in many cases, can be even more disabling than the motor symptoms.

Pascual-Leone, Director of BIDMC's Berenson-Allen Center for Noninvasive Brain Stimulation, will oversee a three-year $1.498 million grant to investigate the use of repetitive transcranial magnetic stimulation (rTMS) therapy to control symptoms of Parkinson's disease. As part of the study, 160 patients will be enrolled in clinical trials at BIDMC and at three other North American centers including the University of Florida in Gainesville, the University of California in Los Angeles, and the Toronto (Canada) Western Research Institute-University of Toronto.

"Depression is very common among patients with Parkinson's disease and evidence suggests that it is not merely a response to chronic illness or motor impairments but, in fact, results from factors related to the degenerative brain process itself," notes Pascual-Leone, whose pioneering work has demonstrated that TMS therapy in which a mild electric current is delivered through a magnetic coil placed over a patient's scalp to help adjust brain signals that have gone awry can successfully treat depression in patients who have not responded to other therapies.

"Often patients with Parkinson's disease have significant motor problems despite treatment with medications," explains Pascual-Leone. "In our study, noninvasive brain stimulation will target one or both of two brain regions involved in motor or mood symptoms. We predict that rTMS will improve motor symptoms, depression, or both, depending on which brain regions are stimulated, and consequently, will become a valuable adjunct to medications."

In the second MJFF-funded project, Daniel Tarsy, MD, Director of BIDMC's Parkinson's Disease Center, will lead a study comparing two types of speech and voice therapy to determine which is more effective in treating the decreased voice volume experienced by many Parkinson's patients.

"Impaired speech can cause patients to suffer distress, social embarrassment and social isolation," explains Tarsy. "Musical therapy is currently being used for rehabilitation from other types of neurological conditions, such as language impairment following stroke. If singing therapy can also improve voice and speech disorders resulting from Parkinson's disease, this would represent an important alternative to existing speech therapy techniques."


Contact: Bonnie Prescott
Beth Israel Deaconess Medical Center

Related medicine news :

1. BIDMC Chairman of Neurology Clifford B. Saper, M.D., Ph.D., elected to Institute of Medicine
2. Low-Carb Diet Referenced in BIDMC Study Not Related to Atkins
3. BIDMC scientists receive creativity awards from Prostate Cancer Foundation
4. Biotech company cofounded by BIDMC scientists targets natural killer T-cells
5. Healthcare Data Services (HDS) Announces Contract with Beth Israel Deaconess Physician Organization (BIDPO) and Beth Israel Deaconess Medical Center (BIDMC)
6. BIDMC Dyslexia Research Lab celebrates 25th anniversary
7. Scientists find molecular trigger that helps prevent aging and disease
8. Chinese Scientists Develop Database on the Liver
9. Scientists Grow New Penile Tissue in the Lab
10. Social Network for Translational Scientists Launched
11. Antipsychotic Medications Cause Substantial Weight Gain in Children and Adolescents, According to Scientists at the Feinstein Institute for Medical Research and Zucker Hillside Hospital
Post Your Comments:
(Date:6/26/2016)... ... ... PawPaws brand pet supplements owned by Whole Health Supply is ... of felines. The formula is all-natural and is made from Chinese herbs that have ... Kidney Support Supplement Soft Chews are Astragalus Root Extract and Rehmannia Root Extract ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery ... of Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , ... for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey ...
(Date:6/25/2016)... ... 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his ... David Geffen School of Medicine at UCLA. He trained in Internal Medicine at Scripps ... in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to ...
(Date:6/24/2016)... ... ... A recent article published June 14 on E Online details ... to state that individuals are now more comfortable seeking to undergo not only the ... and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians (BHP) notes ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension Association ... it will receive two significant new grants to support its work to advance ... 25th anniversary by recognizing patients, medical professionals and scientists for their work in ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... 27, 2016  VMS Rehab Systems, Inc. ( ... whatever measures required to build a strong and stable ... currently listed on the OTC Markets-pink current trading platform. ... CEO, "We are seeing an anomaly in market trading ... only by the Company, but shareholders and market players ...
(Date:6/24/2016)... , June 24, 2016  Global Blood ... biopharmaceutical company developing novel therapeutics for the treatment ... today announced the closing of its previously announced ... stock, at the public offering price of $18.75 ... offering were offered by GBT. GBT estimates net ...
(Date:6/24/2016)... 2016 The Academy of Managed Care Pharmacy ... that would allow biopharmaceutical companies to more easily share ... formulary and coverage decisions, a move that addresses the ... The recommendations address restrictions in the sharing ... drug label, a prohibition that hinders decision makers from ...
Breaking Medicine Technology: